Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ALLOVIRPAR

Market Cap 49.21M 42.5M 39.17M 36.66M 68.71M 4.68B 69.77M 462M 180M 2.28B 185M 181M 7.88B P/E Ratio 2023
-0.37x
P/E Ratio 2024 -0.82x
Enterprise Value -69.08M -59.66M -54.98M -51.46M -96.44M -6.57B -97.94M -649M -253M -3.2B -259M -254M -11.07B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day+6.24%
Current month-53.31%
Current year-53.31%
3 years 4.54
Extreme 4.54
131.56
5 years 4.54
Extreme 4.54
607.43
10 years 4.54
Extreme 4.54
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -164M -152M -142M -266M -18.1B -270M -1.79B -698M -8.81B -715M -699M -30.5B -58.77M -50.76M -46.77M -43.78M -82.05M -5.59B -83.32M -552M -215M -2.72B -221M -216M -9.41B
Net Debt -157M -135M -125M -117M -219M -14.88B -222M -1.47B -573M -7.24B -587M -575M -25.07B -118M -102M -94.15M -88.13M -165M -11.24B -168M -1.11B -433M -5.47B -444M -434M -18.95B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
15/06/26 4.580 $ +5.77% 19,074
12/06/26 4.330 $ -0.69% 34,257
11/06/26 4.360 $ +4.81% 60,023
10/06/26 4.160 $ +1.84% 47,849
09/06/26 4.085 $ -2.04% 103,686
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!